Abstract | OBJECTIVE: METHODS: RESULTS: Thirteen patients (9 female/4 male) underwent vocal fold botulinum toxin injection for refractory PVFMD. The average dose was 2.55 units per vocal fold (range 1.75-5.5 units). The average number of injections was 3.85 (range 1-12 injections). Eleven of 13 (84.6%) patients experienced improvement in dyspnea symptoms, with two of 11 (18.2%) having complete resolution of symptoms. There was a statistically significant improvement in DSI scores because the mean preinjection DSI was 30.43 and improved to 17.43 postinjection (P = 0.017). Temporary breathy voice quality was experienced by all patients with no other adverse side effects. CONCLUSION: Vocal fold botulinum toxin injection is a safe and effective treatment option for PVFMD and should be considered in patients with refractory dyspnea symptoms following appropriate medical therapy and respiratory retraining protocols. LEVEL OF EVIDENCE:
|
Authors | Brad deSilva, Drew Crenshaw, Laura Matrka, L Arick Forrest |
Journal | The Laryngoscope
(Laryngoscope)
Vol. 129
Issue 4
Pg. 808-811
(04 2019)
ISSN: 1531-4995 [Electronic] United States |
PMID | 30548857
(Publication Type: Evaluation Study, Journal Article)
|
Copyright | © 2018 The American Laryngological, Rhinological and Otological Society, Inc. |
Chemical References |
- Neurotoxins
- Botulinum Toxins
|
Topics |
- Adolescent
- Adult
- Aged
- Botulinum Toxins
(administration & dosage)
- Dyspnea
(drug therapy, etiology)
- Female
- Humans
- Injections
- Male
- Middle Aged
- Neurotoxins
(administration & dosage)
- Retrospective Studies
- Severity of Illness Index
- Treatment Outcome
- Vocal Cord Dysfunction
(complications, drug therapy)
- Vocal Cords
(drug effects)
- Young Adult
|